Kenvue Q2 2026 earnings: Sales and EPS rise as margins narrow

Kenvue (NYSE: KVUE) reported fiscal Q2 2026 net sales of $3.955 billion, up 3.0% year over year, while diluted EPS increased 9% to $0.24 from $0.22. All three business segments delivered organic growth, but inflation, tariffs, transactional foreign exchange and higher brand support contributed to narrower profit margins.

Core financial results

For the quarter ended June 28, organic sales increased 1.6%, consisting of 0.9% favorable value realization and 0.7% volume growth. Foreign currency added another 1.4 percentage points to reported net sales growth.

Net income and EPS increased faster than operating income, even as both GAAP and adjusted margins contracted. The following figures are for the fiscal quarter, with dollar amounts in millions except per-share data.

Organic sales and the adjusted figures are non-GAAP measures. Kenvue uses them to separate underlying operating trends from currency movements and specified special items.

Business and segment performance

Skin Health and Beauty posted the fastest growth, while Self Care grew more slowly and experienced a volume decline. Each segment benefited from foreign currency translation during the quarter.

Skin Health and Beauty’s growth was supported by Hair Care and Face Care, e-commerce activity and products including OGX Pro Growth + Peptide and Neutrogena Ultra Sheer Sun. Neutrogena improved U.S. household penetration for a third consecutive quarter.

Self Care returned to organic growth in the U.S., supported by e-commerce, Zyrtec in Allergy and Pepcid in Digestive Health. Tylenol consumption trends improved sequentially, although historically low out-of-season incidence affected the Pain and Cough and Cold businesses.

Essential Health’s growth was volume-led. Wound Care and Baby Care more than offset a decline in Oral Care, while distribution gains and product activity supported results in several regions.

Kenvue also received FDA approval for Tylenol with Naproxen, an over-the-counter fixed-dose combination of acetaminophen and naproxen sodium. The product received three years of exclusivity and is expected to become available at major U.S. retailers, although Kenvue did not provide a sales estimate.

Lower tax rate lifted EPS despite margin pressure

Sales increased 3.0%, but operating income rose only about 1% because gross-margin pressure limited operating leverage. Kenvue attributed the lower gross margin to inflation, tariffs and unfavorable transactional foreign exchange, partially offset by supply-chain productivity savings and favorable value realization. Higher brand support also weighed on operating margin, while restructuring and other cost-optimization savings provided a partial offset.

Below the operating line, net interest expense declined to $90 million from $94 million. More importantly, the effective tax rate fell to 23.7% from 28.6%, reflecting the release of a valuation allowance, a favorable geographic earnings mix and tax-law changes. These factors helped net income and diluted EPS grow considerably faster than operating income, meaning the EPS increase was not driven solely by stronger operating profitability.

Cash flow and balance sheet

Cash-flow figures cover the first six months of fiscal 2026 rather than Q2 alone. Six-month operating cash flow increased to $1.2 billion from $1.0 billion, as higher net income was partially offset by greater use of working capital.

Capital expenditures declined to $0.2 billion from $0.3 billion, helping non-GAAP free cash flow increase to $1.0 billion from $0.8 billion. Cash and cash equivalents were $1.1 billion at June 28, 2026, unchanged from December 28, 2025, while total debt remained at $8.5 billion.

Management perspective and transaction context

CEO Kirk Perry said the company’s transformation remained on track, with continued emphasis on operating efficiencies and strategic brand investment. The 2026 Restructuring Initiative is intended to simplify the operating model and supply chain and is expected to generate approximately $250 million of pre-tax restructuring expenses and other charges during fiscal 2026.

Kenvue remains subject to a definitive agreement under which Kimberly-Clark will acquire all outstanding Kenvue shares in a cash-and-stock transaction. Shareholders of both companies approved the required proposals, and the U.S. antitrust waiting period expired in February. Closing is expected in the fourth quarter of 2026, subject to foreign regulatory approvals and other customary conditions.

Because of the pending transaction, Kenvue did not provide forward-looking financial guidance and did not hold a quarterly conference call.

Recent insider transactions

The supplied six-month insider summary shows 261,190 shares purchased through 15 transactions and 42,191 shares sold through two transactions, resulting in net purchases of 218,999 shares. Total insider holdings were listed at approximately 998,400 shares. Transaction-level information with a clearly identified direction and value was available for the following two sales.

The available data does not provide complete transaction-level details for the purchases, so no conclusion about insider sentiment can be drawn from the aggregate figures alone.

Risks investors need to watch

• Continued margin pressure: Inflation, tariffs and transactional currency effects reduced gross margin, while increased brand support contributed to the decline in adjusted operating margin.
• Uneven underlying demand: Self Care organic sales grew only 0.6% and volume declined 0.6%, with low seasonal incidence affecting parts of the Pain and Cough and Cold portfolio.
• Restructuring execution: The planned operating-model and supply-chain changes carry approximately $250 million of expected fiscal 2026 pre-tax charges and depend on successful implementation.
• Transaction uncertainty and limited visibility: The Kimberly-Clark acquisition still requires foreign regulatory approvals and other closing conditions. Kenvue’s decision not to issue guidance also limits visibility into results before the expected closing.

Summary

Kenvue’s fiscal Q2 2026 results showed broad-based but moderate sales growth, led by Skin Health and Beauty. EPS benefited from a lower tax rate and reduced interest expense, while operating performance remained constrained by inflation, tariffs, transactional currency effects and higher brand spending. The main issues ahead are margin stabilization, Self Care volume trends, restructuring execution and completion of the pending Kimberly-Clark transaction.